Director, COSMOS Pharmaceutical Corporation
Other assets (est.): the sum of each year's after-tax income (pay + dividends in own name − estimated taxes and social insurance) and dividends retained by asset-management companies (less about 20% corporate tax), for the years we have data. Spending, real estate, donations and savings from earlier years are not reflected.
| Company | Held by | Shares | Stake | Price | Value | Dividends |
|---|---|---|---|---|---|---|
| COSMOS Pharmaceutical Corporation 3349 · FY ending May 2026 · Director |
Own name | 2,102,000 | — | ¥6,024 | ¥12.7B | ¥172M |